Katharina Seystahl
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC cancer 2024; 24:82.
Jan 15, 2024A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Jan 15, 2024BMC cancer 2024; 24:82
Mastall Maximilian, Roth Patrick, Bink Andrea, Maranta Angela Fischer, Läubli Heinz, Hottinger Andreas Felix, Hundsberger Thomas, Migliorini Denis, Ochsenbein Adrian F, Seystahl Katharina, Imbach Lukas L, Hortobágyi Tibor, Held Leonhard, Weller Michael, Wirsching Hans-Georg
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
Stadler C, Gramatzki D, Le Rhun E, Hottinger A, Hundsberger T, Roelcke U, Läubli H, Hofer S, Seystahl K, Wirsching H, Weller M, Roth P. Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older. Neurooncol Pract 2023; 11:132-141.
Oct 20, 2023Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
Oct 20, 2023Neurooncol Pract 2023; 11:132-141
Stadler Christina, Gramatzki Dorothee, Le Rhun Emilie, Hottinger Andreas Felix, Hundsberger Thomas, Roelcke Ulrich, Läubli Heinz, Hofer Silvia, Seystahl Katharina, Wirsching Hans-Georg, Weller Michael, Roth Patrick
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 2012; 69:95-101.
Nov 22, 2012Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Nov 22, 2012Eur Neurol 2012; 69:95-101
Seystahl Katharina, Wiestler Benedikt, Hundsberger Thomas, Happold Caroline, Wick Wolfgang, Weller Michael, Wick Antje